MPM Oncology Impact Management »

Hillevax shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Hillevax (HLVX) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Hillevax

Tip: Access up to 7 years of quarterly data

All positions including Hillevax held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Hillevax by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $9.3M 645k 14.46

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Insmed Incorporated Common (INSM)
Olema Pharmaceuticals Common (OLMA)
iTeos Therapeutics Common (ITOS)
Crinetics Pharmaceuticals Common (CRNX)
Madrigal Pharmaceuticals Common (MDGL)
Iovance Biotherapeutics Common (IOVA)
Natera Common (NTRA)
Mirum Pharmaceuticals Common (MIRM)
Ultragenyx Pharmaceutical Common (RARE)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Guardant Health Common (GH)
Disc Medicine Common (IRON)
Alkermes Common (ALKS)
Edgewise Therapeutics Common (EWTX)

View all positions for MPM Oncology Impact Management

Top funds holding Hillevax

Frazier Life Sciences Management
Tang Capital Management
BlackRock
BlackRock
Franklin Resources
Deerfield Management Company
Carlyle
Deep Track Capital
Vanguard Group
Henderson Group
Braidwell
StepStone
Samsara BioCapital
MPM Oncology Impact Management
Geode Capital Management

View all funds holding Hillevax